Sign In
Buy ZTS
$77.59
+1.20 (+1.57%)
At Close: Jun 03, 2026
2 Magnificent Dividend Stocks to Buy Now and Hold Forever
07:15am, Wednesday, 08'th Oct 2025
Few stocks are worth holding onto forever. Those that do tend to have certain traits, including a strong position in an industry with excellent growth prospects and strong, consistent financial result
My 2 Favorite Stocks to Buy Right Now
04:20am, Sunday, 05'th Oct 2025
The S&P 500 continues to advance to new all-time highs, delivering total returns of 15.2% so far in 2025. However, much of this run stems from the "Magnificent Seven" and other massive technology stoc
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
07:00pm, Thursday, 02'nd Oct 2025
Explore the exciting world of Zoetis (ZTS -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends a
Top 15 High-Growth Dividend Stocks For October 2025
10:58pm, Wednesday, 01'st Oct 2025
The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 29'th Sep 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks is more attractive t
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
07:16pm, Friday, 26'th Sep 2025
Zoetis (ZTS) concluded the recent trading session at $143.5, signifying a +1.68% move from its prior day's close.
Pet Pain For Investor Gain
10:19am, Friday, 26'th Sep 2025
ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
08:30am, Tuesday, 23'rd Sep 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
07:15pm, Monday, 15'th Sep 2025
In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
10:56am, Monday, 15'th Sep 2025
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
12:40pm, Friday, 12'th Sep 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks is more attractive to valu
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
12:09pm, Friday, 12'th Sep 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
07:16pm, Tuesday, 09'th Sep 2025
Zoetis (ZTS) reached $149.79 at the closing of the latest trading day, reflecting a -1.29% change compared to its last close.
Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:16pm, Monday, 08'th Sep 2025
Zoetis Inc. (NYSE:ZTS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Kristin Peck - CEO & Director Wetteny Joseph - Executive VP & CFO Con
